Study of folate receptor-positive circulating tumor cells combined with tumor markers for the diagnosis of lung cancer
Objective To investigate the effectiveness of folate receptor-positive circulating tumor cells(FR+-CTC)alone and in combination with tumor markers such as carcinoembryonic antigen(CEA)and CYFRA21-1 in the diagnosis of lung cancer.Methods Clinical data of patients with pulmonary nodules treated in the Sichuan Provincial People's Hospital from December 2019 to October 2022 were collected.The patients were divided into a benign group(n=188)and a malignant group(412)according to nodule pathological properties.The relationship between FR+-CTC and lung cancer was analyzed.The diagnostic value of FR+-CTC combined with of the tumor markers for lung cancer was explored.Results The level of FR+-CTC in the malignant group was higher than that in the benign group.The differences in FR+-CTC levels among different pathological types,TNM stages,and clinical stages in the malignant group were statistically significant(P<0.05).The sensitivity and specificity of FR+-CTC in the diagnosis of lung cancer alone were significantly better than those of the two tumor markers,and the specificity of FR+-CTC in the diagnosis of lung cancer was improved after combination with the two tumor markers(P<0.05).Conclusions FR+-CTC has outstanding diagnostic ability for lung cancer.It can provide references for patient progression and prognosis assessment.The combination of tumor markers can improve the specificity of lung cancer diagnosis.
NETL
NSTL
万方数据
